Synthesis of Cycloruthenated Compounds as Potential Anticancer Agents

✍ Scribed by Lida Leyva; Claude Sirlin; Laura Rubio; Cecilia Franco; Ronan Le Lagadec; John Spencer; Pierre Bischoff; Christian Gaiddon; Jean-Philippe Loeffler; Michel Pfeffer

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 232 KB
• Volume: 2007
• Category: Article
• ISSN: 1434-1948
• DOI: 10.1002/ejic.200601149

✦ Synopsis

Abstract

A library of 19 cycloruthenated derivatives is constructed by making use of the well‐known cyclometalation reaction. Their geometries are modified in a straightforward manner by addition of either mono‐ or bidentate ligands, such as bipyridine, phenanthroline, 1,2‐bis(diphenylphosphanyl)ethane, dimethylphenylphosphane, triphenylphosphane, and 1,3,5‐triaza‐7‐phosphatricyclo[3.3.1.1]decane (PTA) ligands, to cationic cycloruthenated centers. The antitumor properties of the compounds thus obtained are investigated in order to compare them with recently reported ruthenium complexes and cisplatin. IC~50~ values against mammalian cells (A‐172, HCT‐116, and RDM‐4) are determined for the library compounds and some of them, such as those derived from orthoruthenated phenylpyridine and a bidentate N,N ligand, display activity of the same order of magnitude as cisplatin. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)